• Department of Thoracic Surgery, Northern Jiangsu People's Hospital, Yangzhou, 225001, Jiangsu, P. R. China;
SHU Yusheng, Email: shuyusheng65@163.com
Export PDF Favorites Scan Get Citation

Lung cancer has a high morbidity and mortality, and invasion is one of the major factors that cause recurrence and death in lung cancer patients. Tumor-associated macrophages (TAMs) are cells that have the potential to secrete cytokines, growth hormones, inflammatory substrates, and protein hydrolases, which are associated with the growth, invasion and metastasis of tumors. In this article, we will explore the various chemicals that are manufactured to promote the invasion of lung cancer, as well as the numerous clinical therapeutic features that TAMs possess in the treatment of lung cancer. In addition, we look at the possibility that TAMs might be beneficial in the treatment of lung cancer. We have an innovative investigation of the huge variety of complex substances generated by TAMs, with the goal of determining whether or not the molecules under investigation have the potential to serve as new therapeutic targets. Throughout the whole of the presentation, a significant focus is placed on doing in-depth research to ascertain whether TAMs have the capability to reinforce as viable carriers for unique and creative medications. This not only provides novel concepts for the creation of new targeted therapies but also leads to the development of brand-new, cutting-edge methods for the manufacture of individualized medicines and drug carriers.

Citation: REN Qinglin, WU Jun, CHEN Yong, SHU Yusheng. Research advances of tumor-associated macrophages in lung cancer invasion and treatment. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(12): 1773-1778. doi: 10.7507/1007-4848.202205048 Copy

  • Previous Article

    The role of conversion surgery in the treatment of locally advanced unresectable non-small cell lung cancer
  • Next Article

    Thioredoxin-1: A potential target for prevention of heart-related reactive oxygen species injury